OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Cancer is 69. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
The impact of the COVID-19 pandemic on cancer care	358
Pan-cancer image-based detection of clinically actionable genetic alterations	324
Pan-cancer computational histopathology reveals mutations, tumor composition and prognosis	322
Circulating tumor DNA and liquid biopsy in oncology	303
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab	241
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer	233
Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer	226
Cancer vaccines: the next immunotherapy frontier	201
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma	197
Overcoming therapy resistance in EGFR-mutant lung cancer	187
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression	169
A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors	160
Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities	159
Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4+ and PDPN+ CAFs to clinical outcome	153
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer	142
Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity	142
Fatty acid synthesis is required for breast cancer brain metastasis	142
Gradient of Developmental and Injury Response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity	140
The metabolic landscape of RAS-driven cancers from biology to therapy	137
Cancer-associated fibroblasts in the single-cell era	134
Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells	130
The current paradigm and challenges ahead for the dormancy of disseminated tumor cells	126
A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology	124
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma	121
Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology	118

Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer	118
Artificial intelligence in histopathology: enhancing cancer research and clinical oncology	112
EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer	110
Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity	110
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy	110
Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas	107
A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy	105
Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial	104
A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity	101
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study	101
Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia	99
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma	99
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia	99
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity	96
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort	94
The immuno-oncological challenge of COVID-19	94
Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes	93
Bystander IFN-γ activity promotes widespread and sustained cytokine signaling altering the tumor microenvironment	92
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors	91
Applications of organoids for cancer biology and precision medicine	90
Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients	87
Translational advances in pancreatic ductal adenocarcinoma therapy	87
A systematic CRISPR screen defines mutational mechanisms underpinning signatures caused by replication errors and endogenous DNA damage	86
Long-distance modulation of bystander tumor cells by CD8+ T-cell-secreted IFN-γ	86
SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer	84
Three-dimensional imaging mass cytometry for highly multiplexed molecular and cellular mapping of tissues and the tumor microenvironment	84
The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response	83
Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer	82
Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism	81
α-Ketoglutarate attenuates Wnt signaling and drives differentiation in colorectal cancer	81
Targeting public neoantigens for cancer immunotherapy	79
Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy	78
A small-molecule allosteric inhibitor of BAX protects against doxorubicin-induced cardiomyopathy	78
Single-cell analyses reveal YAP/TAZ as regulators of stemness and cell plasticity in glioblastoma	78
Resistance to natural killer cell immunosurveillance confers a selective advantage to polyclonal metastasis	77
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer	74
eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer	73
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity	73
The cGAS–STING pathway and cancer	73
The T cell differentiation landscape is shaped by tumour mutations in lung cancer	72
Emerging strategies for treating metastasis	71
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia	71
Super enhancers define regulatory subtypes and cell identity in neuroblastoma	71
MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis	70